Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis

OBJECTIVE: Sporadic fatal adverse events have been reported during treatment of multiple sclerosis with alemtuzumab. To provide a systematic overview, we searched the centralized European Medicines Agency database of suspected adverse reactions related to medicinal products (EudraVigilance) for fata...

Descripción completa

Detalles Bibliográficos
Autores principales: Holmøy, Trygve, Fevang, Børre, Olsen, David Benee, Spigset, Olav, Bø, Lars
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Note
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6689881/
https://www.ncbi.nlm.nih.gov/pubmed/31405369
http://dx.doi.org/10.1186/s13104-019-4507-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6689881/
https://www.ncbi.nlm.nih.gov/pubmed/31405369
http://dx.doi.org/10.1186/s13104-019-4507-6

Ejemplares similares